title: Outcome of fertility-preserving treatment in young women with endometrial carcinomas.
abstract: OBJECTIVE
  To evaluate the outcome of conservative treatment of young women with endometrial cancer.
  
  
  METHODS
  Observational study.
  
  
  METHODS
  Gifu University Hospital, Japan from 1988 to 2002.
  
  
  METHODS
  Twelve women with endometrial cancer, FIGO IA estimated by MRI under 35 years.
  
  
  METHODS
  Patients were treated with medroxyprogestreone acetate (400-600 mg/day) for 6-10 months, with endometrial curettage performed every four weeks.
  
  
  METHODS
  Response to therapy, pregnancies and reoccurrence of disease during follow up over a 30-month period.
  
  
  RESULTS
  All cases had pathological complete remissions within 6-10 months. Seven of 10 wishing to have babies conceived, and five of them were delivered of full-term babies. Eight of nine cases receiving long term follow up (over 30 months) developed recurrent disease, with four opting for hysterectomy. No patient developed distant metastases or had disease-related death.
  
  
  CONCLUSIONS
  Conservative therapy is feasible in carefully selected young women with endometrial cancer. Recurrence rates were high during long term observation even after pathological complete remissions. Therefore, close follow up is recommended.
authors.affiliation: Department of Obstetrics and Gynecology, Gifu University School of Medicine, Gifu 500-8705, Japan.
authors.forename: K
authors.initials: K
authors.lastname: Niwa
authors.forename: K
authors.initials: K
authors.lastname: Tagami
authors.forename: Z
authors.initials: Z
authors.lastname: Lian
authors.forename: K
authors.initials: K
authors.lastname: Onogi
authors.forename: H
authors.initials: H
authors.lastname: Mori
authors.forename: T
authors.initials: T
authors.lastname: Tamaya
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy / Q000473:pathology / Q000601:surgery; D000328:Adult; D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage*; D002277:Carcinoma / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D018196:Carcinoma, Adenosquamous / Q000188:drug therapy / Q000473:pathology / Q000601:surgery; D015331:Cohort Studies; D003131:Combined Modality Therapy / Q000379:methods; D004107:Dilatation and Curettage / Q000379:methods; D016889:Endometrial Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D004717:Endometrium / Q000473:pathology; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007247:Infertility, Female / Q000517:prevention & control*; D017258:Medroxyprogesterone Acetate / Q000008:administration & dosage*; D009364:Neoplasm Recurrence, Local / Q000209:etiology; D011247:Pregnancy; D011252:Pregnancy Complications, Neoplastic / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D011256:Pregnancy Outcome; D016896:Treatment Outcome
chemical_list: D018931:Antineoplastic Agents, Hormonal; D017258:Medroxyprogesterone Acetate